Bristol Myers Squibb has announced that Dr Monica Shaw joins the company’s commercial leadership team as Senior Vice President, Major Markets.
In this role, Monica oversees the company’s largest markets outside of the U.S., including Canada and Western Europe, all of which are significant growth drivers for Bristol Myers Squibb as the company launches new innovative medicines, while helping patients prevail over serious disease.
Monica joins Bristol Myers Squibb from Oncopeptides, where she served as Chief Executive Officer. Previously, she held international leadership roles at GSK/ViiV Healthcare, Merck Serono and Novartis and has launched more than 15 products through Phase III to commercialization. Monica brings broad experience having worked across immunology, dermatology, oncology, virology, neurology and rare diseases. Dr Shaw began her career as a physician with the National Health Service in the United Kingdom, working across different hospital specialties.
Monica will be based in Zurich and replaces Adam Lenkowsky, who was appointed Executive Vice President and Chief Commercial Officer in April 2023. Lenkowsky assumed the role previously held by Christopher Boerner, PhD, who will succeed Giovanni Caforio, MD as Bristol Myers Squibb’s Chief Executive Officer when Caforio retires on November 1, 2023.
Adam Lenkowsky said: “We are thrilled to welcome Monica to our commercial leadership team as our new Head of Major Markets. Monica is inspired by science-led, purpose-focused organizations and fuelled by a drive to increase patient access to medicines. With her vast international experience and successful track record in new launches, she is the perfect leader to help us deliver on our mission of developing new, transformational medicines that benefit patients with serious diseases across the globe.”
Commenting on her appointment, Monica said: “My passion for science has always been rooted in how it could be used to help people and treat diseases. I’m very excited to join Bristol Myers Squibb at a pivotal time for the organization as we renew our product portfolio, grow an already strong pipeline, and bring new treatments to help patients with unmet needs.”
